{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-027504","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.080878+00:00","generated_at":"2026-06-06T06:11:22.976641+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Veru reports Q1 revenue $2.1M, cash $40.6M; FDA clears IND for enobosarm with GLP-1 for weight loss","bullets":["Net revenue $2.1M (down from $2.5M YoY); gross profit $1.2M (up from $0.7M).","Cash $40.6M at Dec 31, 2023, bolstered by $35.2M net proceeds from public offering.","FDA cleared IND for enobosarm in combination with GLP-1 drugs to preserve muscle during weight loss.","Phase 2b obesity study to start by April 2024; top-line results expected by end of calendar 2024.","Enobosarm for metastatic breast cancer funding-dependent; sabizabulin COVID program paused without external funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-027504","json":"https://secwatch.observer/filing/0001193125-24-027504.json","markdown":"https://secwatch.observer/filing/0001193125-24-027504.md","text":"https://secwatch.observer/filing/0001193125-24-027504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312524027504/0001193125-24-027504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312524027504/d671709d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T06:11:22.976641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a3006665d391e4307bfdeb0c17fc292e9fdcd048","claim":"VERU INC. reported financial results for fiscal 2024 first quarter ended December 31, 2023.","evidence_excerpt":"On February 8, 2024, Veru Inc. issued a press release (the “Press Release”) announcing certain financial highlights for the quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/863894/000119312524027504/0001193125-24-027504-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2024 first quarter ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}